


AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the structure



wherein

$Y$  is  $O$


$m$  is 0,

$L$  is a linker comprising 0 carbon atoms, and

$A$  is an activated ester.

2. (cancelled)
3. (previously presented) The compound of claim 1 wherein  $A$  is succinimido-oxycarbonyl.
- 4-20 (cancelled)
21. (previously presented) The compound  $O^6$ -(succinimido-oxycarbonyl-butaryl-aminocaproyl)-lopinavir.

22. (previously presented) The compound O<sup>6</sup>-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir.
- 23-30. (cancelled)
31. (previously presented) A compound having the structure



wherein


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-,

-OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and



P is selected from the group consisting of polypeptides, polysaccharides and synthetic polymers, and

n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

32. (cancelled)

33. (original) The compound of claim 31 wherein P is an aminated dextran.

34. (original) The compound of claim 31 wherein P is bovine serum albumin.

35. (original) The compound of claim 31 wherein P is keyhole limpet hemocyanin.

36. (original) The compound of claim 31 wherein P is *Limulus polyphemus* hemocyanin.

37. (original) The compound of claim 31 wherein P is bovine thyroglobulin.


38-47 (cancelled)

48. (previously presented) The compound O<sup>c</sup>-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir conjugate with KLH.

49. (previously presented) The compound O<sup>c</sup>-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir conjugate with BSA.

50-51 (cancelled)

52. (previously presented) A compound having the structure



wherein


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-,

-OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and




Q is selected from the group consisting of non-isotopic labels,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of Q.

53. (cancelled)

54. (original) The compound of claim 52 wherein Q is biotin.

55. (cancelled)
56. (previously presented) The compound O<sup>6</sup>-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-lopinavir.
- 57-58 (cancelled)
59. (previously presented) An antibody generated in response to a compound having the structure:



wherein


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-,

-OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and



P is selected from the group consisting of polypeptides, a polysaccharides, and synthetic polymers,


and n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

60-65 (cancelled)

66. (original) An antibody generated in response to the compound of claim 48.

67-80 (cancelled)

81. (previously presented) A compound having the structure



wherein

Y is O,

m is 1,

L is a linker comprising from 1 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms may be linked in sequence, and

A is an activated ester.

82. (previously presented) The compound of claim 81 wherein A is succinimido-oxycarbonyl.